Liver fibrosis in the post-HCV era

Seminars in Liver Disease

Volumn 35, Issue 2, 2015, Pages 157-165

  Pinzani, Massimo ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

antifibrotic; fibrosis; hepatitis C virus; interferon free regimens; noninvasive

Indexed keywords

ALPHA INTERFERON; ANTIFIBROTIC AGENT; ENTECAVIR; TENOFOVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CLINICAL ASSESSMENT; COMORBIDITY; DISEASE COURSE; EPIGENETICS; HEREDITY; HUMAN; LIVER FIBROSIS; MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); COMPLICATION; HEPATITIS C, CHRONIC; LIVER; LIVER CIRRHOSIS; PATHOLOGY;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS;

EID: 84929334376     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0035-1550056     Document Type: Article

References (69)

1. Miller M. H., Agarwal K., Austin A., et al. British Viral Hepatitis group; British Society of Gastroenterology Liver Committee; British Association for the Study of Liver; Scottish Society of Gastroenterology; Scottish Viral Hepatitis group; Scottish Viral Hepatitis Nurses group. Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther: 2014; 39 12 1363 1375
2. Pawlotsky J. M. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology: 2014; 146 5 1176 1192
3. Toy M. Cost-effectiveness of viral hepatitis B & C treatment. Best Pract Res Clin Gastroenterol: 2013; 27 6 973 985
4. Zeuzem S. Decade in review-HCV: hepatitis C therapy-a fast and competitive race. Nat Rev Gastroenterol Hepatol: 2014;; Epub ahead of print
5. Poynard T., McHutchison J., Manns M., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology: 2002; 122 5 1303 1313
6. Morgan R. L., Baack B., Smith B. D., Yartel A., Pitasi M., Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med: 2013; 158 (5 Pt 1): 329 337
7. van der Meer A. J., Veldt B. J., Feld J. J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA: 2012; 308 24 2584 2593
8. Veldt B. J., Heathcote E. J., Wedemeyer H., et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med: 2007; 147 10 677 684
9. Fabrizi F., Dixit V., Messa P. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies. J Med Virol: 2013; 85 6 1019 1027
10. Gisbert J. P., García-Buey L., Pajares J. M., Moreno-Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther: 2005; 21 6 653 662
11. Takahashi K., Nishida N., Kawabata H., Haga H., Chiba T. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med: 2012; 51 19 2745 2747
12. Brown A., Goodman Z. Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs. Expert Rev Gastroenterol Hepatol: 2012; 6 2 187 198
13. Calvaruso V., Craxì A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int: 2014; 34 01 85 90
14. Marcellin P., Gane E., Buti M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet: 2013; 381 9865 468 475
15. Chang T. T., Liaw Y. F., Wu S. S., et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology: 2010; 52 3 886 893
16. Iredale J. P., Benyon R. C., Pickering J., et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest: 1998; 102 3 538 549
17. Krizhanovsky V., Yon M., Dickins R. A., et al. Senescence of activated stellate cells limits liver fibrosis. Cell: 2008; 134 4 657 667
18. Troeger J. S., Mederacke I., Gwak G. Y., et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology: 2012; 143 4 1073 83.e22
19. Kisseleva T., Cong M., Paik Y., et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A: 2012; 109 24 9448 9453
20. Pellicoro A., Ramachandran P., Iredale J. P., Fallowfield J. A. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol: 2014; 14 3 181 194
21. Schuppan D., Ruehl M., Somasundaram R., Hahn E. G. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis: 2001; 21 3 351 372
22. Issa R., Zhou X., Constandinou C. M., et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology: 2004; 126 7 1795 1808
23. Pellicoro A., Aucott R. L., Ramachandran P., et al. Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosis. Hepatology: 2012; 55 6 1965 1975
24. Pellicoro A., Ramachandran P., Iredale J. P. Reversibility of liver fibrosis. Fibrogenesis Tissue Repair: 2012; 5 (Suppl 1 Proceedings of Fibroproliferative disorders: from biochemical analysis to targeted therapiesPetro E Petrides and David Brenner) S26
25. Guido M., Mangia A., Faa G.; Gruppo Italiano Patologi Apparato Digerente (GIPAD); Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP). Chronic viral hepatitis: the histology report. Dig Liver Dis: 2011; 43 04 S331 S343
26. Patel K., Nelson D. R., Rockey D. C., et al. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol: 2008; 6 2 242 247
27. Garcia-Tsao G., Friedman S., Iredale J., Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology: 2010; 51 4 1445 1449
28. Rosselli M., MacNaughtan J., Jalan R., Pinzani M. Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut: 2013; 62 9 1234 1241
29. Desmet V. J., Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol: 2004; 40 5 860 867
30. Younossi Z., Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis: 2014; 46 5 05 S186 S196
31. Lemoine M., Thursz M. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas. Semin Liver Dis: 2014; 34 1 89 97
32. Jepsen P., Vilstrup H., Andersen P. K. The clinical course of cirrhosis: The importance of multi-state models and competing risks analysis. Hepatology: 2014
33. Tsochatzis E. A., Bosch J., Burroughs A. K. New therapeutic paradigm for patients with cirrhosis. Hepatology: 2012; 56 5 1983 1992
34. D'Amico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol: 2006; 44 1 217 231
35. Arvaniti V., D'Amico G., Fede G., et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology: 2010; 139 4 1246 1256, 1256.e1-1256.e5
36. Fede G., D'Amico G., Arvaniti V., et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol: 2012; 56 4 810 818
37. Bruno S., Crosignani A., Facciotto C., et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology: 2010; 51 6 2069 2076
38. Calvaruso V., Bavetta M. G., Ferraro D., et al. Risk of disease decompensation and HCC in patients with HCV cirrhosis nonresponder to PEG IFN plus RBV. Hepatology: 2012; 56 (S1): 253A
39. Novo E., Marra F., Zamara E., et al. Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut: 2006; 55 8 1174 1182
40. Pinzani M., Vizzutti F. Fibrosis and cirrhosis reversibility: clinical features and implications. Clin Liver Dis: 2008; 12 4 901 913
41. Fernández M., Semela D., Bruix J., Colle I., Pinzani M., Bosch J. Angiogenesis in liver disease. J Hepatol: 2009; 50 3 604 620
42. D'Amico G., Pasta L., Morabito A., et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther: 2014; 39 10 1180 1193
43. Lee Y. A., Friedman S. L. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res: 2014; 107 23 30
44. Lens S., Mariño Z., Forns X. Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease. Dig Liver Dis: 2014; 46 05 S197 S205
45. Colombo M., Iavarone M. Role of antiviral treatment for HCC prevention. Best Pract Res Clin Gastroenterol: 2014; 28 5 771 781
46. McGivern D. R., Lemon S. M. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene: 2011; 30 17 1969 1983
47. Hernandez-Gea V., Toffanin S., Friedman S. L., Llovet J. M. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology: 2013; 144 3 512 527
48. Coulouarn C., Clément B. Stellate cells and the development of liver cancer: therapeutic potential of targeting the stroma. J Hepatol: 2014; 60 6 1306 1309
49. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol: 2001; 34 5 730 739
50. Krawczyk M., Müllenbach R., Weber S. N., Zimmer V., Lammert F. Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol: 2010; 7 12 669 681
51. Zimmer V., Lammert F. Genetics and epigenetics in the fibrogenic evolution of chronic liver diseases. Best Pract Res Clin Gastroenterol: 2011; 25 2 269 280
52. Patin E., Kutalik Z., Guergnon J., et al. Swiss Hepatitis C Cohort Study Group; International Hepatitis C Genetics Consortium; French ANRS HC EP 26 Genoscan Study Group. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology: 2012; 143 5 1244 52.e1, 12
53. Rüeger S., Bochud P. Y., Dufour J. F., et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut: 2014
54. Costentin C. E., Trabut J. B., Mallet V., et al. Management of hepatitis C virus infection in heavy drinkers. Alcohol Alcohol: 2013; 48 3 337 342
55. Bruggmann P., Dampz M., Gerlach T., Kravecz L., Falcato L. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. Drug Alcohol Depend: 2010; 110 1-2 167 171
56. Deltenre P., Louvet A., Lemoine M., et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol: 2011; 55 6 1187 1194
57. D'Ambrosio R., Aghemo A., Rumi M. G., et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology: 2012; 56 2 532 543
58. Calvaruso V., Burroughs A. K., Standish R., et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology: 2009; 49 4 1236 1244
59. Calvaruso V., Di Marco V., Bavetta M. G., et al. Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis. Aliment Pharmacol Ther: 2014
60. Carrión J. A., Navasa M., Bosch J., Bruguera M., Gilabert R., Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl: 2006; 12 12 1791 1798
61. Vizzutti F., Arena U., Romanelli R. G., et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology: 2007; 45 5 1290 1297
62. Colecchia A., Montrone L., Scaioli E., et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology: 2012; 143 3 646 654
63. Chen S. H., Li Y. F., Lai H. C., et al. Noninvasive assessment of liver fibrosis via spleen stiffness measurement using acoustic radiation force impulse sonoelastography in patients with chronic hepatitis B or C. J Viral Hepat: 2012; 19 9 654 663
64. Hézode C., Castéra L., Roudot-Thoraval F., et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther: 2011; 34 6 656 663
65. Stasi C., Arena U., Zignego A. L., et al. Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. Dig Liver Dis: 2013; 45 10 840 843
66. D'Ambrosio R., Aghemo A., Fraquelli M., et al. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol: 2013; 59 2 251 256
67. Pinzani M., Vizzutti F., Arena U., Marra F. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol: 2008; 5 2 95 106
68. Schuppan D., Pinzani M. Anti-fibrotic therapy: lost in translation? J Hepatol: 2012; 56 01 S66 S74
69. Hytiroglou P., Snover D. C., Alves V., et al. Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol: 2012; 137 1 5 9